News
MSD adds new indication for Welireg in rare tumours
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
News
AbbVie bags first approval for cancer ADC Emrelis
AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
Oncology
The mesenchymal stem cell’s superpower: Hacking the TME
What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.
News
GSK pays $1.2bn for liver drug as it culls TIGIT programme
GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
News
Bayer CEO confident firm can cope with Xarelto hit
Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
